Compare
Elicio Therapeutics, Inc. vs HCW Biologics Inc. vs Gain Therapeutics, Inc. vs Yarrow Bioscience, Inc.
| Latest fiscal year | Elicio Therapeutics, Inc. ELTX | HCW Biologics Inc. HCWB | Gain Therapeutics, Inc. GANX | Yarrow Bioscience, Inc. YARW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $54.2K | n/a | $570.0K |
| Revenue growth (YoY) | n/a | -97.9% | n/a | +13.8% |
| Gross margin | n/a | 20.0% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$39.57M | -$7.96M | -$20.16M | -$26.48M |
| EPS (Diluted) | -$2.58 | -$10.63 | -$0.61 | -$0.62 |
| Operating cash flow | -$36.95M | -$13.39M | -$18.47M | -$33.12M |
| Free cash flow | -$36.97M | -$13.39M | n/a | -$33.12M |
| Cash & equivalents | $18.56M | $1.95M | $20.84M | $24.03M |
| Total assets | $25.86M | $24.52M | $22.82M | $30.16M |
| Total liabilities | $24.23M | $21.76M | $4.25M | $2.40M |
| Shareholders' equity | $1.64M | $2.76M | $18.56M | $27.77M |
| Return on year-end equity | n/m | -287.9% | -108.6% | -95.4% |
| Shares outstanding | 17.80M | n/a | 42.07M | 33.32M |
Revenue, most recent five fiscal years
| Fiscal year | Elicio Therapeutics, Inc. | HCW Biologics Inc. | Gain Therapeutics, Inc. | Yarrow Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $2.30M Ended 2022-12-31 | $54.2K Ended 2025-12-31 | $55.2K Ended 2023-12-31 | $570.0K Ended 2025-12-31 |
| 1 year earlier | $28.31M Ended 2021-12-31 | $2.57M Ended 2024-12-31 | $140.1K Ended 2022-12-31 | $501.0K Ended 2024-12-31 |
| 2 years earlier | $2.88M Ended 2020-12-31 | $2.84M Ended 2023-12-31 | $165.0K Ended 2021-12-31 | $424.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $6.72M Ended 2022-12-31 | $28.9K Ended 2020-12-31 | $477.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $931.0K Ended 2021-12-31 |